| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
2'-O-MOE-U does not have a specific biological target itself; it is a chemical building block. Its function is to be incorporated into oligonucleotides to improve their pharmacokinetic properties, including nuclease resistance and binding affinity to target RNA. The MOE modification provides a ΔTm increase of 0.9-1.6°C per modification vs. 0.5-0.7°C for 2'-OMe, ensuring superior target affinity. It enables the construction of ASOs and siRNA therapeutics with extended tissue half-lives (~30-day tissue half-life) and reduced non-specific protein binding.
|
|---|---|
| ln Vitro |
In vitro, 2'-O-MOE-U is used as a monomer in the solid-phase synthesis of oligonucleotides. The resulting MOE-modified oligonucleotides exhibit enhanced stability against nuclease degradation and improved target binding affinity compared to unmodified oligonucleotides. The modification is compatible with standard solid-phase oligonucleotide synthesis.
|
| ln Vivo |
In vivo, 2'-O-MOE-U is not used as a therapeutic agent itself. However, oligonucleotides synthesized using this building block have been used in vivo as therapeutic agents, with the MOE modification improving their pharmacokinetic properties, such as prolonged half-life and enhanced tissue distribution. The favorable hepatotoxicity profile vs. LNA makes it ideal for chronic liver-targeted therapies.
|
| Enzyme Assay |
In vitro non-cell-based assays for 2'-O-MOE-U typically involve its use in standard oligonucleotide synthesis protocols. The compound is coupled to a growing oligonucleotide chain using phosphoramidite chemistry. The purity and identity of the synthesized oligonucleotides are confirmed by HPLC and mass spectrometry. The compound is supplied at ≥98% purity (HPLC), suitable for GMP oligonucleotide drug substance manufacturing.
|
| Cell Assay |
In vitro cell-based assays are not typically performed with 2'-O-MOE-U itself, as it is a synthetic intermediate. However, the MOE-modified oligonucleotides synthesized from it are tested in cell-based assays to evaluate their efficacy in modulating target gene expression. These assays measure target mRNA knockdown by qPCR and protein levels by Western blotting or ELISA.
|
| Animal Protocol |
In vivo animal experiments are not conducted with 2'-O-MOE-U directly. Instead, MOE-modified oligonucleotides synthesized using this building block are administered to animal models to study their pharmacokinetics, pharmacodynamics, and therapeutic efficacy. Tissue half-life, biodistribution, and target engagement are commonly assessed.
|
| ADME/Pharmacokinetics |
2'-O-MOE-U has a molecular weight of 804.86 g/mol and the formula C42H53N4O10P. It is a nucleoside phosphoramidite and a 2'-modified nucleoside. It is stored at 4°C, protected from light. Its purity is typically ≥98% (mixture of isomers). It is used for DNA synthesis and is suitable for molecular biology applications.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for 2'-O-MOE-U are not provided, as it is a chemical building block. However, oligonucleotides containing MOE modifications have been extensively studied and are generally well-tolerated. The MOE modification has a favorable hepatotoxicity profile compared to LNA.
|
| References | |
| Additional Infomation |
2'-O-MOE-U is a key building block for second-generation antisense oligonucleotides (ASOs) and siRNA therapeutics. The MOE modification is widely used to enhance the drug-like properties of oligonucleotides. It is a cornerstone component in numerous FDA-approved oligonucleotide drugs and late-stage clinical candidates. It is intended for research use.
|
| Molecular Formula |
C42H53N4O10P
|
|---|---|
| Molecular Weight |
804.864792585373
|
| Exact Mass |
804.349
|
| CAS # |
163759-97-5
|
| PubChem CID |
129896826
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.74
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
57
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)N(C(C)C)P(OCCC#N)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N2C=CC(=O)NC2=O)COC(C3=CC=CC=C3)(C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC
|
| InChi Key |
ZLOKLUONKGURQI-UAQIPLLRSA-N
|
| InChi Code |
InChI=1S/C42H53N4O10P/c1-29(2)46(30(3)4)57(54-25-11-23-43)56-38-36(55-40(39(38)52-27-26-49-5)45-24-22-37(47)44-41(45)48)28-53-42(31-12-9-8-10-13-31,32-14-18-34(50-6)19-15-32)33-16-20-35(51-7)21-17-33/h8-10,12-22,24,29-30,36,38-40H,11,25-28H2,1-7H3,(H,44,47,48)/t36-,38-,39-,40-,57?/m1/s1
|
| Chemical Name |
3-[[(2R,3R,4R,5R)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-(2,4-dioxopyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2425 mL | 6.2123 mL | 12.4245 mL | |
| 5 mM | 0.2485 mL | 1.2425 mL | 2.4849 mL | |
| 10 mM | 0.1242 mL | 0.6212 mL | 1.2425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
